Equity Field Notes from temporal sources

[DanWebzster]

GBT Ph2 SCD drug voelotor trial had strong results for its primary endpoint (hemolytic anemia)

Voxelotor has already received Breakthrough Therapy designation from the FDA as well as Priority Medicine designation and Orphan designation from the EMA.

If the FDA grants Accelerated Approval designation, Voxelotor will be on the market in 2019.

FDA has already expressed the importance of new therapeutics for SCD.